WO2000037083A1 - Composition pharmaceutique orale anti-oestrogenique - Google Patents

Composition pharmaceutique orale anti-oestrogenique Download PDF

Info

Publication number
WO2000037083A1
WO2000037083A1 PCT/US1999/027933 US9927933W WO0037083A1 WO 2000037083 A1 WO2000037083 A1 WO 2000037083A1 US 9927933 W US9927933 W US 9927933W WO 0037083 A1 WO0037083 A1 WO 0037083A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
antiestrogen
dosage form
oral
oral dosage
Prior art date
Application number
PCT/US1999/027933
Other languages
English (en)
Inventor
Frank Everett Bowen
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to AU21568/00A priority Critical patent/AU2156800A/en
Publication of WO2000037083A1 publication Critical patent/WO2000037083A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

L'invention concerne une forme posologique orale de formule (I), qui peut être administrée à un mammifère femelle, à jeun ou non. Ladite forme contient l'anti-oestrogène de formule (I), une dose efficace d'au moins un désintégrant et une dose efficace d'un tensioactif, suffisante pour qu'un rapport surface sous la courbe¿non à jeun?/surface sous la courbeà jeun de moins d'environ 15 soit obtenu.
PCT/US1999/027933 1998-12-18 1999-12-16 Composition pharmaceutique orale anti-oestrogenique WO2000037083A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21568/00A AU2156800A (en) 1998-12-18 1999-12-16 Oral antiestrogen pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21643198A 1998-12-18 1998-12-18
US09/216,431 1998-12-18

Publications (1)

Publication Number Publication Date
WO2000037083A1 true WO2000037083A1 (fr) 2000-06-29

Family

ID=22807038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027933 WO2000037083A1 (fr) 1998-12-18 1999-12-16 Composition pharmaceutique orale anti-oestrogenique

Country Status (3)

Country Link
AR (1) AR021719A1 (fr)
AU (1) AU2156800A (fr)
WO (1) WO2000037083A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034661A1 (fr) * 2004-09-30 2006-04-06 Pliva-Lachema A.S. Procede de production de forme pharmaceutique solide orale, et forme pharmaceutique solide orale resultante
US8703810B2 (en) 2010-06-10 2014-04-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9018244B2 (en) 2011-12-16 2015-04-28 Olema Pharmaceuticals, Inc. Benzopyran compounds, compositions and uses thereof
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026201A1 (fr) * 1995-02-21 1996-08-29 Endorecherche, Inc. Composes contenant du benzopyranne et techniques d'application
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
WO1999063974A2 (fr) * 1998-06-11 1999-12-16 Endorecherche, Inc. Utilisations medicales d'un modulateur de recepteur d'oestrogenes selectif en association avec des precurseurs de steroides sexuels

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026201A1 (fr) * 1995-02-21 1996-08-29 Endorecherche, Inc. Composes contenant du benzopyranne et techniques d'application
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
WO1999063974A2 (fr) * 1998-06-11 1999-12-16 Endorecherche, Inc. Utilisations medicales d'un modulateur de recepteur d'oestrogenes selectif en association avec des precurseurs de steroides sexuels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAUTHIER S ET AL.: "(S)-(+)-4-[7-(2,2,-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-Dimethylpropanoate (EM-800): A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen", JOURNAL OF MEDICINAL CHEMISTRY., vol. 40, 1997, AMERICAN CHEMICAL SOCIETY., US, pages 2117 - 2122, XP002133672, ISSN: 0022-2623 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034661A1 (fr) * 2004-09-30 2006-04-06 Pliva-Lachema A.S. Procede de production de forme pharmaceutique solide orale, et forme pharmaceutique solide orale resultante
US8703810B2 (en) 2010-06-10 2014-04-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9078871B2 (en) 2010-06-10 2015-07-14 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
US9018244B2 (en) 2011-12-16 2015-04-28 Olema Pharmaceuticals, Inc. Benzopyran compounds, compositions and uses thereof

Also Published As

Publication number Publication date
AR021719A1 (es) 2002-07-31
AU2156800A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
US10912763B2 (en) Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
EP2600846B1 (fr) Forme pharmaceutique comprenant une 6'-fluoro-(n-méthyl- ou n,n-diméthyl-)-4-phényl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
EP2062572A1 (fr) Compositions pharmaceutiques
EP2046285A1 (fr) Granulés et comprimés comprenant de l'oxycodone et se désintégrant par voie orale
WO2013098402A1 (fr) Combinaison pharmaceutique de fingolimod et de nabiximols
KR100465895B1 (ko) 파라세타몰을 포함하는 경구용 정제
EP0749308B1 (fr) Comprimes enrobes de paracetamol et de domperidone
KR101237646B1 (ko) 생체이용률이 개선된 셀레콕시브 함유 고체 분산체, 이를 포함하는 약학 조성물 및 이의 제조방법
US20040229939A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
JP2013533881A (ja) バノキセリンを含有する医薬組成物
TW201813645A (zh) 含鹽皮質激素受體拮抗劑的藥物組合物及其用途
US7189412B2 (en) Fenofibrate-containing composition
WO2000037083A1 (fr) Composition pharmaceutique orale anti-oestrogenique
JPH10226644A (ja) 医薬組成物
EP3517104A1 (fr) Formulation nanoparticulaire comprenant un inhibiteur de mpges -1
US20190209551A1 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
WO2009056256A1 (fr) Utilisation d'acétate de mégestrol à solubilité améliorée pour traiter la cachexie cancéreuse
KR20230163511A (ko) 미분화된 솔라베그론 조성물 및 사용 방법
EA042299B1 (ru) Фармацевтические композиции и их применения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase